Ethynyl estradiol (57-63-6) video
Ethynyl estradiol (57-63-6) Specification:
|Chemical Structure:||Product Name: Ethynyl estradiol|
|Cas No.: 57-63-6|
|Molecular Formula: C20H24O2|
|Molecular Weight: 296.4|
|Storage: Dry, dark and at 0 – 4 C for short term (days to weeks)|
|Documents(COA & HPLC etc.): Available|
Ethynyl estradiol (57-63-6) Description:
Ethinyl Estradiol powder is a semisynthetic estrogen. The mechanism of action of ethinyl estradiol is as an Estrogen Receptor Agonist. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in oral contraceptives. Ethinyl estradiol binds to the estrogen receptor complex and enters the nucleus, activating DNA transcription of genes involved in estrogenic cellular responses. This agent also inhibits 5-alpha reductase in epididymal tissue, which lowers testosterone levels and may delay progression of prostatic cancer. In addition to its antineoplastic effects, ethinyl estradiol protects against osteoporosis. In animal models, short-term therapy with this agent has been shown to provide long-term protection against breast cancer, mimicking the antitumor effects of pregnancy.
- 1: Archer DF, Thomas MA, Conard J, Merkatz RB, Creasy GW, Roberts K, Plagianos M, Blithe D, Sitruk-Ware R. Impact on hepatic estrogen-sensitive proteins by a 1-year contraceptive vaginal ring delivering Nestorone® and ethinyl estradiol. Contraception. 2016 Jan;93(1):58-64. doi: 10.1016/j.contraception.2015.09.008. Epub 2015 Sep 25. PubMed PMID: 26408374.
- 2: Lobo Abascal P, Luzar-Stiffler V, Giljanovic S, Howard B, Weiss H, Trussell J. Differences in reporting Pearl Indices in the United States and Europe: Focus on a 91-day extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation. Eur J Contracept Reprod Health Care. 2016 Feb;21(1):88-91. doi: 10.3109/13625187.2015.1059416. Epub 2015 Jun 26. PubMed PMID: 26115381.
- 3: Waellnitz K, Duijkers I, Klipping C, Rautenberg T, Rohde B, Zurth C. A two-centre, open-label, randomised study of ovulation inhibition with three transdermal contraceptive patches, each containing different amounts of ethinyl estradiol and gestodene in healthy, young women. J Obstet Gynaecol. 2016 Jan;36(1):106-13. doi: 10.3109/01443615.2015.1041882. Epub 2015 Sep 30. PubMed PMID: 26421957.
- 4: Patel G, King A, Dutta S, Korb S, Wade JR, Foulds P, Sumeray M. Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects. J Clin Pharmacol. 2016 Jan;56(1):47-55. doi: 10.1002/jcph.581. Epub 2015 Sep 10. PubMed PMID: 26120010.